4.6 Review

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

Journal

NATURE REVIEWS ENDOCRINOLOGY
Volume 19, Issue 4, Pages 201-216

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41574-022-00783-3

Keywords

-

Ask authors/readers for more resources

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) have incretin activity and play important roles in regulating glucose and lipid metabolism beyond the pancreas. They also have effects on weight loss, atherosclerosis, cardiorenal protection, and other physiological processes. Understanding the mechanisms of GIP and GLP1 action can lead to the development of new treatments for obesity and type 2 diabetes mellitus.
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion. The emergence of GIP receptor (GIPR)-GLP1 receptor (GLP1R) co-agonists has fostered growing interest in the actions of GIP and GLP1 in metabolically relevant tissues. Here, we update concepts of how these hormones act beyond the pancreas. The actions of GIP and GLP1 on liver, muscle and adipose tissue, in the control of glucose and lipid homeostasis, are discussed in the context of plausible mechanisms of action. Both the GIPR and GLP1R are expressed in the central nervous system, wherein receptor activation produces anorectic effects enabling weight loss. In preclinical studies, GIP and GLP1 reduce atherosclerosis. Furthermore, GIPR and GLP1R are expressed within the heart and immune system, and GLP1R within the kidney, revealing putative mechanisms linking GIP and GLP1R agonism to cardiorenal protection. We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPR-GLP1R co-agonist tirzepatide, as well as the GIPR antagonist-GLP1R agonist AMG-133. Collectively, we update translational concepts of GIP and GLP1 action, while highlighting gaps, areas of uncertainty and controversies meriting ongoing investigation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available